Kailera Therapeutics
A clinical-stage biopharma company advancing a diverse therapeutic pipeline aimed at delivering innovative treatments for obesity and related conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $400m | Series A | |
| Total Funding | 000k | ||
Related Content
Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on the rapidly growing market for obesity and related metabolic conditions. The company launched in October 2024 with a substantial $400 million Series A financing, co-led by prominent investors Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with Lyra Capital also participating. This significant initial funding allows Kailera to bypass early research stages and advance a portfolio of clinical-stage assets. The company's business model centers on acquiring and developing promising drug candidates. In May 2024, Kailera secured exclusive rights to develop and commercialize a portfolio of four metabolic disease assets outside of Greater China from Jiangsu Hengrui Pharmaceuticals.
The leadership team is composed of seasoned biotech executives. CEO Ron Renaud has a notable history of leading companies to successful acquisitions, including Cerevel Therapeutics (acquired by AbbVie), Translate Bio (acquired by Sanofi), and Idenix Pharmaceuticals (acquired by Merck & Co.). The board is chaired by John F. Milligan, the former President and CEO of Gilead Sciences, who was instrumental in its growth into a global biopharmaceutical leader.
Kailera's product pipeline is diverse, featuring both injectable and oral therapies targeting chronic weight management. Its most advanced program is KAI-9531, an injectable dual agonist targeting GLP-1 and GIP receptors. This candidate has already produced compelling results in Phase 2 trials for obesity and type 2 diabetes conducted in China. The pipeline also includes KAI-7535, an oral small molecule GLP-1 receptor agonist; an oral tablet formulation of KAI-9531; and KAI-4729, an injectable tri-agonist targeting GLP-1, GIP, and glucagon receptors. This multi-faceted approach, with various mechanisms and delivery routes, is designed to address complex patient needs in a market currently dominated by major pharmaceutical players.
Keywords: Kailera Therapeutics, obesity treatment, metabolic conditions, GLP-1 agonist, GIP agonist, dual agonist, tri-agonist, weight management therapy, clinical-stage biopharmaceutical, Ron Renaud, John F. Milligan, injectable therapies, oral therapies, KAI-9531, KAI-7535, KAI-4729, Bain Capital Life Sciences, Atlas Venture, RTW Investments, chronic weight management, Jiangsu Hengrui Pharmaceuticals